SEGMENT INFORMATION (Tables)

6 Months Ended

Mar. 31, 2023

SEGMENT INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the three-month period ended March 31, 2023 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	255,626	$	—	$	41,828	$	297,454
Service revenues		83,906		—		85,152		169,058
Clinical laboratory service revenues		—		3,971,582		—		3,971,582
Less intersegment revenues		—		(30,480)		—		(30,480)
Total revenues	$	339,532	$	3,941,102	$	126,980	$	4,407,614
Gross profit	$	215,477	$	1,650,113	$	(58,155)	$	1,807,435
(Loss) income from segment operations (a)	$	(1,054,123)	$	492,288	$	(914,736)	$	(1,476,571)

Information regarding operations by segment for the three-month period ended March 31, 2022 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	—	$	180,023	$	228,328	$	408,351
Service revenues		158,243		—		90,447		248,690
Clinical laboratory service revenues		—		5,623,922		—		5,623,922
Less intersegment revenues		—		(133,680)		—		(133,680)
Total revenues	$	158,243	$	5,670,265	$	318,775	$	6,147,283
Gross profit	$	158,243	$	2,335,169	$	(4,927)	$	2,488,485
(Loss) income from segment operations (a)	$	(1,049,207)	$	1,084,388	$	(1,292,632)	$	(1,257,451)

Information regarding operations by segment for the six-month period ended March 31, 2023 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	383,132	$	—	$	430,718	$	813,850
Service revenues		205,649		—		195,470		401,119
Clinical laboratory service revenues		—		8,537,397		—		8,537,397
Less intersegment revenues		—		(82,000)		—		(82,000)
Total revenues	$	588,781	$	8,455,397	$	626,188	$	9,670,366
Gross profit	$	386,401	$	3,583,332	$	215,385	$	4,185,118
(Loss) income from segment operations (a)	$	(1,906,376)	$	1,602,172	$	(1,389,451)	$	(1,693,655)

Information regarding operations by segment for the six-month period ended March 31, 2022 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	—	$	522,844	$	711,818	$	1,234,662
Service revenues		247,681		—		140,282		387,963
Clinical laboratory service revenues		—		8,973,580		—		8,973,580
Less intersegment revenues		—		(283,216)		—		(283,216)
Total revenues	$	247,681	$	9,213,208	$	852,100	$	10,312,989
Gross profit	$	247,681	$	3,155,859	$	194,083	$	3,597,623
(Loss) income from segment operations (a)	$	(1,973,984)	$	749,400	$	(2,189,032)	$	(3,413,616)

Schedule of reconciliation of segment loss from operations to corporate loss

Three-Month Period Ended:	March 31,
	2023		2022
Loss from operations of reportable segments	$	(1,476,571)	$	(1,257,451)
General corporate expenses (b)		(1,227,453)		(896,785)
Interest income		3,639		5,540
Unrealized gain on change in fair value of warrants classified as a liability		3,250,900		782,500
Transaction cost allocated to warrant liabilities		—		(391,335)
Other income (expense), net		661		(2,266)
Consolidated income (loss) before provision for income taxes	$	551,176	$	(1,759,797)

Six-Month Period Ended:	March 31,
	2023		2022
Loss from operations of reportable segements	$	(1,693,655)	$	(3,413,616)
General corporate expenses (b)		(2,229,347)		(3,447,197)
Interest income		7,325		5,813
Unrealized gain on change in fair value of warrants classified as a liability		613,100		782,500
Transaction cost allocated to warrant liabilities		—		(391,335)
Other income (expense), net		9,507		(16,873)
Consolidated loss before provision for income taxes	$	(3,293,070)	$	(6,480,708)